阿莫西林舒巴坦钠和头孢哌酮他唑巴坦钠治疗下呼吸道感染的成本-效果分析.pdfVIP

·药物经济学· 时英西林/舒巳姐钩和头抱，氏嗣/他哇巳姐钩 始疗下呼吸道感染的成本 E 效果分析 自 瑶\刘玉琴，烧艳辉(北京大学深圳医院药刻科，深圳市 518036) 中图分类号 R978.1 文献栋t只码 B 文章编号 1672 叫 2124 (2010) 03 响。251 喃 02 摘 要 阔的:对阿英西林/舒巴坦纳和头抱啄嗣/他唆巴坦锅治疗下呼吸道感染进行药物经济学分析，为临床提供用药参考方 索。方法:采用统计研究和成本 4 效果分析方法，对下呼吸道感染治疗成本进行药物绞济学许价。结果:阿美西林/舒已放纳和头 J也曾在制/他甲虫巴坦纳治疗下呼吸遥感被总有效*分别为 88.0% 和 90.0% ，效采差异无K藉，除意义 (P O. 05); 治疗成本分别;为 948.57 元和2529.45元，差异明显。结论:阿莱西林/舒巳坦纳治疗下呼吸道感染比头袍民嗣/他吆已走里销量1 经济，符合药物经济 学原则。 关键诩 阿英西林/舒已放纳;头抱旅嗣/他吧业已放纳;下呼吸i越感染;成本-效果分析 Cost - effectiveness Analysis of Amoxicillin / Sulbactam Sodium vs. Cefoperazone/ Tazobactam Sodium in tbe Treatment of Lower Respiratory Infection BAI Yao , LIU YU -qin , RAO Yan-hui (Dept. of Phannacy , Peking University Shenzhen Hospital , Shenzhen 518036 , China) ABSTRACT OBJECTIVE: To conduct a pharmacoeconomic analysis of amoxicillin sodium/sulbactam sodium versus cefoperazone/tazobactam sodium for lower respiratory infection 80 as to provide reference of clinical medication. METHODS: The statistical research and cost - effectíveness analysis were employed to conduct the pharmacoeconomic assessment of the treatment costs for lower respiratory infection. RESULTS: The total effective rates of amoxicillin I sulbactam sodium and cefopera嚣one/tazobactam sodium were 88.0% and 90. 0% respectively , showing no statistically significant difference between the two schemes (P O. 05 ); however , the costs of two schemes showed statistically significant difference (948.57 Yuan vs. 2 529.45 Yuan). CONCLUSION: Pharmaco - economically , amoxicillín/ sulbactam sodium is more economical than cefoperazone/tazobactam sodium for lower respiratoηinfection ， thus meeting the principle of pharmacoeωnomics. KEY WORDS Amoxicillinl sulbactam sodium; Cefoperazone/tazobactamωdium; l.ower respiratory infec嗣 tion; Cωt - effectiveness analysis 下呼吸i菌感染是最常见的降吸系统疾病，-般要用抗生 咳嗽、咳痰、气促、气嚼